The way we diagnose and treat cancer in pets is evolving, thanks in large part to genomics and precision medicine. And Vidium stands ready to help veterinary teams move into the world of personalized, precision medicine. We combine genomic and molecular diagnostic testing with pathology, providing you with one trusted source for advanced diagnostics.
Our diagnostics leverage the latest science available to provide more information about your patient’s cancer. A better understanding of your patient’s cancer can guide your diagnosis and treatment planning, helping to advance the care of pets with cancer.
mast cell tumor
mutations in KIT, MDR1, and VEGFR2
mutations in TRAF3 and PTEN
mutations in KIT, MDM2, and NRAS
mutations in PTPN11 and TP53
mutation in HER2
Our flagship test, SearchLight DNA, is an extensively validated, next-generation diagnostic test that checks for 120 relevant cancer genes, making it the most informative and scientifically rigorous canine cancer genetic test available.
SpotLight ePARR is a highly accurate and rapid molecular diagnostic test for canine lymphoma that’s setting new standards for quality and transparency in molecular diagnostic testing.
Our specialty pathology team combines extensive expertise in cancer pathology with genomic diagnostics to provide unparalleled advanced cancer diagnostic evaluation for your patients.
At Vidium, our number one goal is to help guide you and your veterinary team through the challenges of managing your patients’ cancer diagnosis. As a company led by veterinarians, we consider ourselves part of the wider animal health team. We understand that genetics, genomics, transcriptomics, and proteomics are complicated. Our team not only understands the science, but also understands that it is our responsibility to deliver that science in a way that is clear, understandable, and actionable. We’re always available to discuss a case or a report and appreciate the opportunity to do so.
The Translational Genomics Research Institute (TGen, an affiliate of City of Hope) is a leader in the genomics revolution. Begun by Dr. Jeffrey M. Trent, the founding Scientific Director of the Human Genome Project, this world-class research institute explores the most advanced areas of genetics in human and animal health. As a subsidiary of TGen, Vidium Animal Health® benefits from the incredible knowledge and research of TGen scientists.
Cancer is scary. After a cancer diagnosis in our pets, we often feel lost and alone. Vidium’s mission is to bring the incredible advances happening in human oncology precision medicine to our beloved pets. Starting with our formative relationship with the Translational Genomics Research Institute (TGen, an affiliate of City of Hope), a leader at the cutting edge of precision medicine, building on our discoveries in canine cancer genetics, and continuing with our rigorous scientific validation of diagnostic assays. Talk to your veterinary team about whether a SearchLight DNA test or a SpotLight ePARR test may be good options for your pet.